| Date | Title | Description |
| 13.11.2024 | Trace Neuroscience: A New Dawn in Genomic Medicine for ALS | In the realm of biopharmaceuticals, a new player has emerged, armed with ambition and a hefty $101 million in Series A funding. Trace Neuroscience is on a mission to reshape the landscape of genomic medicine, particularly for those grapplin... |
| 13.11.2024 | Trace Neuroscience: $101 Million (Series A) Raised To Expand Genomic Medicine Platform | Trace Neuroscience – a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases – announced its launch with a $101 million Series A funding led by Third Rock Ventures, with partic... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 11.06.2024 | QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors | Industry veteran Williamson brings nearly three decades' experience as a leader in neuroscience R&D at organizations including Eli Lilly and Company, Lundbeck, Parexel, and Acadia Pharmaceuticals
Former Karuna CFO Brown brings more than... |
| 02.05.2024 | BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline | - |
| 14.03.2024 | Rare Disease Advocates Learn to Accelerate Therapeutic Development at 9th RARE Drug Development Symposium | RARE Drug Development Symposium
The RARE Drug Development Symposium, hosted by Global Genes and the Orphan Disease Center of the University of Pennsylvania, equips advocates with the knowledge, skills and connections they need to advance th... |
| 05.03.2024 | BridgeBio Pharma Announces Pricing of Public Offering of Common Stock | - |
| 04.03.2024 | BridgeBio Pharma Announces Proposed Public Offering of Common Stock | PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underw... |
| 07.02.2024 | The GLP-1 panic is alive and well | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, all. Damian here with news of a new biotech venture fund, a bold bet against a billion-dollar deal, an... |
| 18.01.2024 | BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines | - |
| 03.11.2022 | BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update | /EIN News/ -- - Reported positive preclinical data for its next-generation KRASG12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3Kα:RAS breaker mechanism in late lead optimization
- Reported positive updated ... |
| 18.11.2021 | BridgeBio Pharma : Secures Up to $750 Million in Non-Dilutive Debt Financing - Form 8-K | BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing
-Innovative financing facility and existing cash balance gives BridgeBio access to over $1.2 billion, which is expected to fully fund the Company's 30+ genetic... |
| 18.11.2021 | BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing | -Innovative financing facility and existing cash balance gives BridgeBio access to over $1.2 billion, which is expected to fully fund the Company’s 30+ genetic disease and cancer pipeline programs into 2024
PALO ALTO, Calif., Nov. 18, 2021 ... |
| 18.11.2021 | BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing | -Innovative financing facility and existing cash balance gives BridgeBio access to over $1.2 billion, which is expected to fully fund the Company’s 30+ genetic disease and cancer pipeline programs into 2024
PALO ALTO, Calif., Nov. 18, 2021 ... |
| 03.11.2021 | BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease | PALO ALTO, Calif., Nov. 3, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient has been dosed in CANaspire,... |
| 29.10.2021 | BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers | PALO ALTO, Calif., Oct. 29, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced two new academic collaborations with Columbia Univ... |
| 12.10.2021 | BridgeBio Pharma : Announces Progress in its KRAS Portfolio, New Gene Therapy Programs, and Updates on Advancements Across its R&D Pipeline Targeting Genetic Diseases and Cancers | PALO ALTO, Calif., Oct. 12, 2021 /PRNewswire/ - BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, is announcing meaningful progress in its KRAS cancer portfolio... |
| 07.10.2021 | BridgeBio Pharma : Announces First Publication of Preclinical Data for its Potentially Best-in-Class SHP2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-smal... | -Preclinical findings that demonstrated efficacy in non-small cell lung cancer (NSCLC) driven by RAS or other MAPK-pathway activating mutations will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer... |
| 15.09.2021 | BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i) | |
| 15.09.2021 | BridgeBio : Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i) | PALO ALTO, Calif., Sept. 15, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and ... |
| 18.08.2021 | BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors | |
| 18.08.2021 | BridgeBio Pharma : Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors | PALO ALTO, CA - August 18, 2021 - BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with cle... |
| 05.08.2021 | BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update | |
| 27.07.2021 | BridgeBio : Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors wi... | PALO ALTO, Calif., July 27, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic di... |
| 27.07.2021 | BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with... | |
| 08.07.2021 | BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions | |
| 08.07.2021 | BridgeBio : Pharma Announces Collaborations with Three Academic Research Institutions | PALO ALTO, Calif., July 8, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and ca... |
| 14.08.2020 | Canada’s Atomwise secures 163M CAD in Series B funding | The AI-driven drug discovery platform was founded in 2012 by Abraham Heifets, Alexander Levy and Dr. Izhar Wallach and was earlier known as Chematria. It was initially a part of University of Toronto’s incubator before associating with Y Co... |
| 11.08.2020 | Perceptive debuts LianBio with cancer and heart disease programs from BridgeBio, MyoKardia | After working in stealth since October, Perceptive Advisors is unveiling its latest biotech: LianBio, which serves the dual mission of bringing much-needed new drugs to China and helping U.S. biotech companies expand their operations into A... |
| 11.08.2020 | Perceptive debuts LianBio with cancer and heart disease programs from BridgeBio, MyoKardia
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | After working in stealth since October, Perceptive Advisors is unveiling its latest biotech: LianBio, which serves the dual mission of bringing much-needed new drugs to China and helping U.S. biotech companies expand their operations into A... |
| 10.06.2020 | BIO: BridgeBio CEO Kumar on its 'hub-and-spoke' model and where else it could work | Five years ago, Neil Kumar, Ph.D., quit his job at Third Rock Ventures to start a new kind of biotech company. The idea was "Moneyball" for biotech—to pick up potential rare disease treatments languishing in academia and to develo... |
| 10.06.2020 | BIO: BridgeBio CEO Kumar on its 'hub-and-spoke' model and where else it could work
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Five years ago, Neil Kumar, Ph.D., quit his job at Third Rock Ventures to start a new kind of biotech company. The idea was "Moneyball" for biotech—to pick up potential rare disease treatments languishing in academia and to develo... |
| 20.12.2019 | Bill Lundberg takes over the reins at Merus; Former Akcea COO Jeffrey Goldberg takes the helm of Immunitas | Bill Lundberg
→ Dutch biotech Merus, who struck up a $200 million bispecific development deal with Incyte in 2016, is losing their CEO Ton Logtenberg. Meanwhile, the company has nominated Sven (Bill) Ante Lundberg to be Lo... |
| 15.10.2019 | BridgeBio terminates effort to acquire remainder of Eidos Therapeutics | Eidos trades publicly on the Nasdaq, and its shares fell 6.5 percent Monday morning following the news, remaining down 3.1 percent Tuesday afternoon. BridgeBio’s shares were up 2 percent.
The subsidiary, which is headquartered in San Franci... |
| 28.05.2019 | BridgeBio files for $225M initial public offering | The company was formed in 2015 and adopted a model developed at the Massachusetts Institute of Technology’s Sloan School of Management, whereby it identifies drugs to treat genetic diseases and also cancers that have clear genetic drivers a... |
| 26.01.2019 | BridgeBio Pharma Closes $299.2 Million Financing Round to Support Its Efforts to Target Genetic Disease at the Source | PALO ALTO, Calif.–(BUSINESS WIRE)–BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million. The round was co-led by existing investors KKR and Viking G... |
| 25.01.2019 | Term Sheet — Friday, January 25 | CHINA’S PRIVATE EQUITY KING
Happy Friday, Term Sheet readers.
Paid Content Keeping business secure in the age of digital privacy From ExtraHop
In a wide-ranging interview, my colleague Shawn Tully spoke with private equity veteran Weijian S... |
| 25.01.2019 | Daily funding roundup - January 25th, 2019 | AirWorks Solutions raised $2.3M; RealBlocks raised $3.1M; 7shifts raised $10M
AirWorks Solutions: AirWorks’ aerial mapping software helps land developers and engineers to evaluate more job sites within their critical planning and acquisitio... |
| 24.01.2019 | BridgeBio Pharma Receives $299.2M |
PALO ALTO, CA, BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million.
>> Click here for more funding data on BridgeBio Pharma
>> To ... |
| 23.01.2019 | BridgeBio Pharma Closes $299.2M Financing Round | BridgeBio Pharma, a Palo Alto, CA-based clinical-stage biopharmaceutical company focused on genetic diseases, raised $299.2m in new financing.
The round was co-led by existing investors KKR and Viking Global Investors, with participation fr... |
| 23.01.2019 | BridgeBio Pharma Closes $299.2 Million Financing Round to Support Its Efforts to Target Genetic Disease at the Source | PALO ALTO, Calif.--(BUSINESS WIRE)--BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million. The round was co-led by existing investors KKR and Viking... |
| 23.01.2019 | BridgeBio Pharma raises $299.2M in financing round | The company plans to use the money support and expand upon existing research and development programs in genetic diseases. BridgeBio’s practice is to find product candidates, sourced from various academic and research institutions and compa... |
| 14.09.2017 | Term Sheet — Thursday, September 14 | UNICORN STATUS
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
Today, we learned that Magic Leap, a Florida-based wearable tech company, is raising $500 million in fresh funding at a valuatio... |
| 13.09.2017 | BridgeBio Pharma expands investor base, raising an additional $135 million, and discloses genetic disease pipeline programs | PALO ALTO, Calif., Sept. 13, 2017 /PRNewswire/ — BridgeBio Pharma, a clinical-stage biopharmaceutical company, today provided further detail on its growing pipeline of genetic disease assets and announced a new financing of $135 million, wi... |
| 13.09.2017 | BridgeBio Pharma Raises Additional $135M in Funding | BridgeBio Pharma, a Palo Alto, CA-based clinical-stage biopharmaceutical company, raised an additional $135m in funding.
The round was co-led by new investor Viking Global Investors and existing investor KKR with participation from existing... |
| 13.09.2017 | A biotech company focused on inherited diseases just raised $135 million from a bunch of Wall Street firms | Courtsey BridgeBio
BridgeBio CEO Neil Kumar
A biotech focused on developing drugs to treat genetic diseases just raised $135 million.
Advertisement
BridgeBio Pharma, which was founded in 2015, builds out subsidiary companies around differen... |
| - | BridgeBio terminates effort to acquire remainder of Eidos Therapeutics | A firm that helps launch biomedical research into new companies has called off a bid to acquire one of its subsidiaries.
Palo Alto, California-based BridgeBio Pharma said Monday that it had terminated a merger process with subsidiary Eidos ... |
| - | BridgeBio Pharma raises $299.2M in financing round | A company focused on developing genetically targeted drugs discovered by academia and then building subsidiary companies around them has raised nearly $300 million in a financing round.
Palo Alto, California-based BridgeBio Pharma said Wedn... |
| - | BridgeBio files for $225M initial public offering | A company that turns research in genetically driven diseases into subsidiary companies has filed to go public.
Palo Alto, California-based BridgeBio said Friday that it had filed a Form S-1 with the Securities and Exchange Commission for th... |
